Latest Breaking News On - Chief medical officer merdad parsey - Page 2 : comparemela.com

International Business: Gilead quarterly revenue drops 4 %, oral Covid drug fails trial

International Business: Gilead quarterly revenue drops 4 %, oral Covid drug fails trial
gdnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gdnonline.com Daily Mail and Mail on Sunday newspapers.

United statesMerdad parseyMichael yeeGilead sciences onGilead sciencesChief medical officer merdad parseyWall street

Gilead quarterly revenue drops 4%, oral COVID drug fails trial

By Deena Beasley (Reuters) -Gilead Sciences on Tuesday said fourth-quarter revenue dipped 4% on lower sales of HIV drugs and its infused COVID-19 treatment .

New jerseyUnited statesLos angelesSonali paulMerdad parseyMichael yeeDeena beasleyGilead sciences onGilead sciencesChief medical officer merdad parseyWall streetReporting by deena beasleyMichael ermanBill berkrot

Gilead s at just the beginning of cell therapy movement: exec

Gilead s at just the beginning of cell therapy movement: exec
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Andrew dickinsonMerdad parseyCindy perettieGilead sciencesFinancial officer andrew dickinsonKite pharmaChief medical officer merdad parseyFierce biotechTizona therapeutics

Gilead quarterly revenue drops 4%, oral COVID drug fails trial

Gilead Sciences on Tuesday said its fourth-quarter revenue dipped 4% on lower sales of HIV drugs and Veklury, an infused drug for hospitalized COVID-19 patients, while its adjusted profit rose 3% due.

Merdad parseyGilead sciences onChief medical officer merdad parseyWall streetReporting by deena beasley editingBill berkrot

Gilead quarterly revenue drops 4%, oral COVID drug fails trial

Gilead Sciences on Tuesday said fourth-quarter revenue dipped 4% on lower sales of HIV drugs and its infused COVID-19 treatment Veklury, and the company forecast weaker-than-expected 2024 sales. For full-year 2024, Gilead said it expects adjusted earnings of $6.85 to $7.25 per share on product sales of $27.1 billion to $27.5 billion. Analysts have projected 2024 earnings of $7.24 per share on revenue of $27.7 billion.

Deena beasleyMerdad parseyGilead sciences onChief medical officer merdad parseyWall streetReporting by deena beasleyBill berkrot